Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00988117 · ClinicalTrials.gov registry record · Phase 4
The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00988117 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 15 participants.
The verdict
NCT00988117, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is an open-label study to investigate the effects of the rivastigmine patch on attention and behavior in Parkinson's disease when associated with memory and/or thinking problems. Rivastigmine (also sold under the name Exelon) is an FDA approved medication used for the treatment of mild to moderate Alzheimer's Disease (AD) and memory or thinking problems due to Parkinson's disease. Recently a rivastigmine patch was developed, which has shown similar effectiveness with fewer side effects and increased caregiver preference when compared to capsules. This is an open-label 12 week study where 15 subjects diagnosed with Parkinson's Disease who have mild to moderate memory and/or thinking complaints will be treated with the rivastigmine patch at UCSF. This study also analyzes the mechanism by which the rivastigmine patch works in people with Parkinson's disease and memory and/or thinking problems.
Interventions
- DRUG Rivastigmine Patch 9.5 cm2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00988117
The ClinicalTrials.gov registry entry for NCT00988117 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivastigmine Patch 9.5 cm2 is the first listed.
NCT00988117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00988117 about?
NCT00988117 is a clinical study titled "The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems". This is an open-label study to investigate the effects of the rivastigmine patch on attention and behavior in Parkinson's disease when associated with memory and/or thinking problems. Rivastigmine (also sold under the name Exelon) is an FDA approved medication used for the treatment of mild to moder...
What is the current status of trial NCT00988117?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2010-04. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00988117?
The interventions under investigation include: Rivastigmine Patch 9.5 cm2 (DRUG).
Who is sponsoring clinical trial NCT00988117?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.